danicamtiv
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Familial Dilated Cardiomyopathy
Conditions
Primary Familial Dilated Cardiomyopathy
Trial Timeline
Aug 4, 2020 → Feb 22, 2024
NCT ID
NCT04572893About danicamtiv
danicamtiv is a phase 2 stage product being developed by Bristol Myers Squibb for Primary Familial Dilated Cardiomyopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT04572893. Target conditions include Primary Familial Dilated Cardiomyopathy.
What happened to similar drugs?
20 of 20 similar drugs in Primary Familial Dilated Cardiomyopathy were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06027437 | Phase 1 | Completed |
| NCT04572893 | Phase 2 | Terminated |
Competing Products
20 competing products in Primary Familial Dilated Cardiomyopathy